State of New Jersey Common Pension Fund D Buys 20,704 Shares of Twist Bioscience Co. (NASDAQ:TWST)

State of New Jersey Common Pension Fund D boosted its stake in shares of Twist Bioscience Co. (NASDAQ:TWST – Get Rating) by 74.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,479 shares of the company’s stock after acquiring an additional 20,704 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Twist Bioscience were worth $2,394,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. KRS Capital Management LLC bought a new position in Twist Bioscience during the 4th quarter worth $46,000. SG Americas Securities LLC increased its stake in shares of Twist Bioscience by 86.4% in the 1st quarter. SG Americas Securities LLC now owns 2,831 shares of the company’s stock valued at $140,000 after purchasing an additional 1,312 shares during the last quarter. Exane Derivatives bought a new position in shares of Twist Bioscience in the 1st quarter valued at $177,000. Spearhead Capital Advisors LLC increased its stake in shares of Twist Bioscience by 45.4% in the 1st quarter. Spearhead Capital Advisors LLC now owns 4,279 shares of the company’s stock valued at $211,000 after purchasing an additional 1,337 shares during the last quarter. Finally, Envestnet Asset Management Inc. bought a new position in shares of Twist Bioscience in the 4th quarter valued at $251,000.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Barclays lifted their price target on Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a research note on Wednesday, July 13th. The Goldman Sachs Group decreased their price target on Twist Bioscience from $105.00 to $55.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 13th. Finally, Robert W. Baird decreased their price target on Twist Bioscience from $70.00 to $43.00 in a research note on Friday, May 6th.

Twist Bioscience Stock Up 0.7 %

Shares of TWST stock opened at $44.93 on Wednesday. The firm has a market capitalization of $2.53 billion, a P/E ratio of -12.14 and a beta of 1.19. Twist Bioscience Co. has a twelve month low of $25.07 and a twelve month high of $139.99. The stock’s fifty day simple moving average is $37.09 and its 200 day simple moving average is $43.28.

Twist Bioscience (NASDAQ:TWST – Get Rating) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($1.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.02. The business had revenue of $48.13 million for the quarter, compared to analyst estimates of $45.25 million. Twist Bioscience had a negative return on equity of 28.88% and a negative net margin of 114.96%. Twist Bioscience’s quarterly revenue was up 54.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.78) EPS. As a group, equities research analysts expect that Twist Bioscience Co. will post -4.85 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO James M. Thorburn sold 923 shares of the stock in a transaction dated Monday, May 23rd. The stock was sold at an average price of $36.90, for a total value of $34,058.70. Following the completion of the sale, the chief financial officer now owns 44,463 shares of the company’s stock, valued at $1,640,684.70. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Twist Bioscience news, CFO James M. Thorburn sold 923 shares of the stock in a transaction that occurred on Monday, May 23rd. The shares were sold at an average price of $36.90, for a total transaction of $34,058.70. Following the completion of the sale, the chief financial officer now owns 44,463 shares of the company’s stock, valued at approximately $1,640,684.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Paula Green sold 10,067 shares of the stock in a transaction that occurred on Wednesday, June 15th. The shares were sold at an average price of $30.47, for a total transaction of $306,741.49. Following the sale, the senior vice president now directly owns 14,727 shares of the company’s stock, valued at approximately $448,731.69. The disclosure for this sale can be found here. Insiders have sold 19,581 shares of company stock worth $654,504 in the last 90 days. Insiders own 3.10% of the company’s stock.

Twist Bioscience Company Profile

(Get Rating)

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.